Clinical trials: Sitagliptin
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin
This study will assess the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and pharmacodynamics (explores what a drug does to the body) of single doses of JNJ-38431055, sitagliptin, and…
- Trial name
- NCT01054118
- Testing
- JNJ-38431055, Sitagliptin 100 mg, JNJ-38431055 + Sitagliptin 100 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus Type 2
CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)
The purpose of this study is to evaluate a pharmacokinetic drug interaction between sitagliptin and lobeglitazone in healthy male volunteers.
- Trial name
- NCT02827890
- Testing
- Januvia Tab. 100mg, Januvia Tab. 100mg + Duvie Tab. 0.5mg
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124495
- Testing
- Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Healthy
The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology
The purpose of this study is to determine the pharmacogenetics, pharmacokinetics, and drug-drug interactions of sitagliptin therapy.
- Trial name
- NCT01112670
- Testing
- Sitagliptin, atorvastatin
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Bioequivalance
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fast Study.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study.
- Trial name
- ACL25-IC002 (NCT07763899)
- Testing
- Sitagliptin/Metformin FDC, Janumet XR
- Where
- Mexico
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ADIUM
Type 2 Diabetes
A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)
A three part study to demonstrate the bioequivalence of a single dose of the Final Market Image (FMI) of sitagliptin/metformin 50/500, 50/850 and 50/1000 mg Fixed-Dose Combination (FDC) tablet and co-administration of…
- Trial name
- NCT00961480
- Testing
- sitagliptin phosphate (+) metformin hydrochloride, Comparator: metformin 500mg, Comparator: sitagliptin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
Pharmacogenetics of Response to Sitagliptin (PRS)
This is a research study to find out how different people respond to a medication called sitagliptin. Sitagliptin is an FDA approved medication that is used to treat diabetes.
- Trial name
- PRS (NCT06813014)
- Testing
- Oral Glucose Tolerance Test
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Healthy
Degradation of the Anorexic Hormone Peptide YY
Peptide YY (PYY) is a gastrointestinal hormone released from the enteroendocrine cell upon food intake. The N-terminal truncated form, PYY3-36, exerts anorexic effects.
- Trial name
- NCT02493959
- Testing
- PYY1-36 infusion, PYY1-36 + sitagliptin, PYY3-36 infusion
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Bioequivalence
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fed Study.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL25-IC003 (NCT07763912)
- Testing
- Janumet XR, Sitagliptin/Metformin FDC
- Where
- Mexico
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ADIUM
Breast Cancer
Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
Background: Breast cancer is the most frequently diagnosed malignancy among women worldwide and a major cause of morbidity and mortality.
- Trial name
- SGLT2i/DPPi (NCT07436663)
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy, Sitagliptin (DPP4 inhibitor), Standard Care (in control arm)
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tanta University
Type 2 Diabetes Mellitus
Vascular Effects of Sitagliptin in Diabetes Mellitus
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid gut hormone secreted in a nutrient-dependent manner that stimulates insulin secretion and inhibits glucagon secretion and gastric emptying, thereby reducing postprandial…
- Trial name
- NCT01096277
- Testing
- Sitagliptin, Control
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hannover Medical School
Atherosclerosis, Inflammation
Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity
Abdominal obesity is a major risk factor for heart attack, stroke, peripheral vascular disease, dementia, cancer and Type 2 diabetes.
- Trial name
- SAVORO (NCT02576288)
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Healthy
Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers
Crossover study to compare the pharmacokinetic characteristics of GLH1SM sustained release tablet and Janumet XR tablet in fasting condition
- Trial name
- NCT03851341
- Testing
- Janumet XR tablet 100/1000 mg, GLH1SM tablet 100/1000 mg
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation
Glucose Homeostasis
Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)
This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin release when GLP-1 is not allowed to be rapidly…
- Trial name
- NCT00947011
- Testing
- Januvia
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy
Sitagliptin and Endothelial Dysfunction
Over the years, numbers of cardioprotective drugs have been evaluated to attenuate lethal ischemia-reperfusion (IR) injuries. There is little study whether sitagliptin protects against endothelial dysfunction induced by IR injury…
- Trial name
- NCT02406950
- Testing
- Sitagliptin
- Where
- South Korea
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Kyunghee University Medical Center
Healthy
Effects of Lansoprazole on Sitagliptin Glucose-lowering Ability in Healthy Males: a Randomised Crossover Study
Oral hypoglycemic medications sometimes do not control type 2 diabetes well. Proton pump inhibitors (PPIs) as adjunctive therapy might improve diabetes control and could enhance the hypoglycemic activity of DPP4, but there is…
- Trial name
- NCT01820104
- Testing
- lansoprazole, 30 mg per day for 6 days
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Diabetes Mellitus, Steroid Diabetes
Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome
The investigators will assess whether the DPP-inhibitor sitagliptin will ameliorate glucocorticoid-induced impairment of glucose metabolism and beta-cell dysfunction and thus could be used as a prophylaxis for…
- Conditions
- Diabetes Mellitus, Steroid Diabetes, Glucocorticoid-induced Diabetes, Beta-cell Function
- Trial name
- SPHINX (NCT00721552)
- Testing
- Sitagliptin 100 mg, Prednisolone 30 mg
- Where
- Netherlands
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Diabetes Mellitus Non-insulin-dependent
An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)
To support the registration of sitagliptin 100mg in china.
- Trial name
- NCT00642798
- Testing
- sitagliptin phosphate
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes
The aim of this trial is to evaluate the safety of single doses of a study drug known as LY3325656 that is given orally to healthy participants and participants with type 2 diabetes.
- Trial name
- NCT03115099
- Testing
- LY3325656, Liraglutide, Sitagliptin
- Where
- 2 sites in Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
Sanford Research/USD proposes to study the combination therapy of oral administration of sitagliptin and lansoprazole versus placebo for the preservation of pancreatic beta cells still present in patients with recent-onset…
- Trial name
- REPAIR-T1D (NCT01155284)
- Testing
- Sitagliptin and Lansoprazole
- Where
- 3 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Sanford Health